Cours suspendu

Communiqués Eiger BioPharmaceuticals

Actions

EIGR

US28249U2042

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets Autres places de cotation 17:27:07 27/09/2024			Varia. 5j.	Varia. 1 janv.
8,500 ^USD	-.--%		-.--%	-

01/10/24	Eiger BioPharmaceuticals se place sous la protection du chapitre 11 de la loi sur les faillites et le plan de liquidation prend effet	CI
30/09/24	Eiger BioPharmaceuticals, Inc. a cessé ses activités	CI

Communiqués

01/10/24	Eiger BioPharmaceuticals : DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE Form 8 K	PU
16/07/24	Eiger BioPharmaceuticals : THIS IS NOT A SOLICITATION OF ACCEPTANCE OR REJECTION OF THE PLAN. THE DEBTORS ARE SEEKING APPROVAL OF THE DISCLOSURE STATEMENT ON A CONDITIONAL BASIS, BUT IT HAS NOT YET BEEN APPROVED BY THE BANKRUPTCY COURT Form 8 K	PU
01/04/24	Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection	AQ
19/01/24	Eiger and Partner, AnGes, Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	AQ
18/01/24	Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	PR
04/01/24	Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split	PR
09/11/23	Eiger BioPharma: Q3 Earnings Snapshot	AQ
09/11/23	Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	PR
12/09/23	Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta	PR
05/09/23	Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference	PR
14/08/23	Eiger BioPharma: Q2 Earnings Snapshot	AQ
14/08/23	Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update	PR
30/06/23	Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide, David Apelian Takes Helm as CEO	AQ
29/06/23	Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO	PR
28/06/23	Eiger BioPharmaceuticals to Host Business Update Call Tomorrow	PR
20/06/23	Eiger BioPharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K	PU
20/06/23	EIGER BIOPHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
11/05/23	Eiger BioPharma: Q1 Earnings Snapshot	AQ
11/05/23	Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update	PR
04/05/23	Eiger BioPharmaceuticals Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	AQ
03/05/23	Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)	PR
14/04/23	EIGER BIOPHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
14/04/23	Eiger BioPharmaceuticals Strengthens Management Team with New Appointments	AQ
17/03/23	EIGER BIOPHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
16/03/23	Eiger BioPharma: Q4 Earnings Snapshot	AQ